What is the average survival time after taking brigatinib/brigatinib?

Brigatinib/Brigatinib (Brigatinib): It is a second-generation targeted drug used to treat ALK-positive non-small cell lung cancer (NSCLC). It has shown widespread concern in the treatment of crizotinib resistance. One of the biggest concerns of many patients after starting brigatinib is "how long can they live?" However, the concept of "average survival" is no longer a fixed number in the era of targeted therapy. The reason is that there are huge differences among patients, including ALK mutation type, disease stage, brain metastasis status, systemic treatment response and other factors, which will have a substantial impact on survival.

From the perspective of global treatment trends, brigatinib can significantly delay disease progression and prolong progression-free survival (PFS) due to its potentALK inhibitory ability and good central nervous system penetration rate. Although individual studies may report some survival data, these data do not provide one-size-fits-all guidance at the individual treatment level. More importantly, as brigatinib gradually becomes the first-line treatment option for ALK-positive patients, the long-term quality of life of patients is expected to be further improved.

In addition, the actual survival time after brigatinib treatment is also related to whether the resistance mechanism can be discovered in time, whether genetic testing is performed regularly, and whether alternative therapies can be quickly accessed. In international treatment practice, many patients can successfully switch to third-generation ALK inhibitors after developing resistance to brigatinib, and some patients even participate in clinical trials of new drugs, thereby continuing to achieve disease control. This means that survival is not static during brigatinib treatment, but can be further extended through dynamic treatment strategies.

Therefore,"average survival time" cannot be used as the only criterion for measuring the efficacy of brigatinib. What is more important for patients is regular imaging follow-up, genetic testing and side effect management to extend the time of disease stabilization and gain more hope for survival in the overall treatment journey.

Reference materials:https://www.alunbrig.com/